CASI Pharmaceuticals Inc
CASI
Company Profile
Business description
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Contact
No. 81, Jianguo Road
Room 1701-1702, China Central Office Tower 1
Huamao Office Building, Chaoyang District
Beijing100025
CHNT: +86 01065618789
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
233
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,529.80 | 9.60 | 0.11% |
| CAC 40 | 7,806.31 | 30.48 | -0.39% |
| DAX 40 | 23,366.40 | 160.61 | -0.68% |
| Dow JONES (US) | 42,051.06 | 89.37 | -0.21% |
| FTSE 100 | 8,539.53 | 45.48 | -0.53% |
| HKSE | 23,380.03 | 260.62 | -1.10% |
| NASDAQ | 19,146.81 | 136.72 | 0.72% |
| Nikkei 225 | 37,755.51 | 372.62 | -0.98% |
| NZX 50 Index | 12,880.82 | 101.56 | 0.79% |
| S&P 500 | 5,892.58 | 6.03 | 0.10% |
| S&P/ASX 200 | 8,297.50 | 17.90 | 0.22% |
| SSE Composite Index | 3,380.82 | 23.13 | -0.68% |